Provenge – Sipuleucel-T may have added benefit in prostate cancer

Sipuleucel-T in prostate cancer: Indication of added benefit – Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.

Prostate cancer – A change in circulating tumor cells detection has high potential in the prediction

Prostate cancer: A change in circulating tumor cells detection has high potential in the prediction – A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels.

Omega 3 and fish oil supplements may increase prostate cancer risk

Study confirms link between omega-3 fatty acids and increased prostate cancer risk — Consumption of fatty fish and fish-oil supplements linked to 71 percent higher risk – A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer.

Prostate cancer – active surveillance and watchful waiting better

Observation is safe, cost-saving in low-risk prostate cancer — Study suggests low-risk patients can forego immediate treatment – Many men with low-risk, localized prostate cancers can safely choose active surveillance or “watchful waiting” instead of undergoing immediate treatment and have better quality of life while reducing health care costs, according to a study by researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital.

New genomic prostate cancer test improves risk assessment and surveillance

New prostate cancer test improves risk assessment — Tool tested by UC San Francisco helps identify those best suited for active surveillance – A new genomic test for prostate cancer can help predict whether men are more likely to harbor an aggressive form of the disease, according to a new UC San Francisco study. The test, which improves risk assessment when patients are first diagnosed, can also aid in determining which men are suitable for active surveillance – a way of managing the disease without direct treatment.

Early onset baldness may raise prostate cancer risk in African American men

Early-onset baldness in African-American men may be linked to prostate cancer – Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Do NOT follow this link or you will be banned from the site!